Pleiotropic effects of mitiglinide in type 2 diabetes mellitus

Journal of International Medical Research

Volumn 37, Issue 6, 2009, Pages 1904-1912

  Konya, Hiroyuki ^a   Miuchi, M ^a   Konishi, K ^a   Nagai, E ^a   Ueyama, T ^a   Kusunoki, Y ^a   Kimura, Y ^a   Nakamura, Y ^a   Ishikawa, T ^a   Inokuchi, C ^a   Katsuno, T ^a   Hamaguchi, T ^a   Miyagawa, J ^a   Namba, M ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Glycaemic control; Lipid metabolism; Meal tolerance test; Mitiglinide; Type 2 diabetes mellitus; Urinary albumin

Indexed keywords

1,5 ANHYDROSORBITOL; ALBUMIN; FATTY ACID; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; IMMUNOREACTIVE INSULIN; MITIGLINIDE;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CLINICAL ARTICLE; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HUMAN; INSULIN RELEASE; LIPID METABOLISM; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEIOTROPY; TREATMENT DURATION; URINARY EXCRETION;

EID: 74949110149     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700628     Document Type: Article

References (20)

1. Garcia MJ, McNamara PM, Gordon T, et al: Morbidity and mortality in diabetics in the Framingham population. Sixteen year followup study. Diabetes 1974; 23: 105-111.
2. Zilversmit DB: Atherogenesis: a postprandial phenomenon. Circulation 1979; 60: 473-485.
3. Ebenbichler CF, Kirchmair R, Egger C, et al: Postprandial state and atherosclerosis. Curr Opin Lipidol 1995; 6: 286-290.
4. Lefèbvre PJ, Scheen AJ: The postprandial state and risk of cardiovascular disease. Diabet Med 1998; 15(suppl 4): S63-S68.
5. Ceriello A: The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 2000; 16: 125-132.
6. Bonora E, Muggeo M: Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia 2001; 44: 2107-2114.
7. Balkau B, Shipley M, Jarrett RJ, et al: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-367.
8. The DECODE study group on behalf of the European Diabetes Epidemiology Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 345: 617-621.
9. Chiasson JL, Josse RG, Gomis R, et al: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494.
10. Cheng AY, Fantus IG: Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005; 172: 213-226.
11. Harada S, Nomura M, Nakaya Y, et al: Nateglinide with glibenclamide examination using the respiratory quotient (RQ). J Med Invest 2006; 53: 303-309.
12. Mogami H, Shibata H, Nobusawa R, et al: Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic β-cell line, MIN 6 cell. Eur J Pharmacol 1994; 269: 293-298.
13. Ohnota H, Koizumi T, Tsutsumi N, et al: Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro- 2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther 1994; 269: 489-495.
14. Assaloni R, Da Ros R, Quagliaro L, et al: Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 2005; 48: 1919-1924.
15. Matthews DR, Hosker JP, Rudenski AS, et al: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
16. Pratley RE, Foley JE, Dunning BE: Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharm Des 2001; 7: 1375-1397.
17. Mori Y, Kitahara Y, Miura K, et al: Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats. Diabetes Obes Metab 2004; 6: 422-431.
18. Mori Y, Kitahara Y, Miura K, et al: Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading. Endocrine 2004; 23: 39-43.
19. Mori Y, Kuriyama G, Tajima N: Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test. Endocrine 2004; 25: 203-206.
20. Chinen I, Shimabukuro M, Yamakawa K, et al: Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology 2007; 148: 160-165.